Wei Zhao

Wei Zhao

Auto-generated profile, based on publicly available information

Wei Zhao

Center for Stem Cell Biology and Tissue Engineering, Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-Sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2019 in Cancer Research
Verified
Journal Article
Open access
PDF file
FLFuxi Li
Fuxi Li
YYYang Yi
Yang Yi
YMYanyan Miao
Yanyan Miao
WLWenyong Long
Wenyong Long
TLTeng Long
Teng Long
WZWei Zhao
Wei Zhao
The N6-methyladenosine (m6A) modification influences various mRNA metabolic events and tumorigenesis, however, its functions in nonsense-mediated mRNA decay (NMD) and whether NMD detects induced carcinogenesis pathways remain undefined. Here, we showed that the m6A methyltransferase METTL3 sustained its oncogenic role by modulating NMD of splicing factors and alternative splicing isoform switches in glioblastoma (GBM). Methylated RNA immunoprecipitation-seq (MeRIP-seq) analyses showed that m6A modification peaks were enriched at metabolic pathway–related transcripts in glioma stem cells (GSC) compared with neural progenitor cells. In addition, the clinical aggressiveness of malignant gliomas was associated with elevated expression of METTL3. Furthermore, silencing METTL3 or overexpressing dominant-negative mutant METTL3 suppressed the growth and self-renewal of GSCs. Integrated transcriptome and MeRIP-seq analyses revealed that downregulating the expression of METTL3 decreased m6A modification levels of serine- and arginine-rich splicing factors (SRSF), which led to YTHDC1-dependent NMD of SRSF transcripts and decreased SRSF protein expression. Reduced expression of SRSFs led to larger changes in alternative splicing isoform switches. Importantly, the phenotypes mediated by METTL3 deficiency could be rescued by downregulating BCL-X or NCOR2 isoforms. Overall, these results establish a novel function of m6A in modulating NMD and uncover the mechanism by which METTL3 promotes GBM tumor growth and progression. Significance: These findings establish the oncogenic role of m6A writer METTL3 in glioblastoma stem cells.

8 June 2018 in Polymer Chemistry
Verified
Journal Article
Closed access
PDF file
GLGuiting Liu
Guiting Liu
QYQijuan Yuan
Qijuan Yuan
GHGeoffrey Hollett
Geoffrey Hollett
WZWei Zhao
Wei Zhao
YKYang Kang
Yang Kang
JWJun Wu
Jun Wu
CD-based host–guest supramolecular hydrogels and their potential biomedical application.

21 August 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
CWChenglei Wu
Chenglei Wu
WCWeixin Chen
Weixin Chen
JHJincan He
Jincan He
SJShouheng Jin
Shouheng Jin
YLYukun Liu
Yukun Liu
WZWei Zhao
Wei Zhao
M 6 A controls the inflammatory response through cross-talk with H3K27me3, indicating the importance of m 6 A in immune homeostasis.

7 December 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YYYang Yi
Yang Yi
IHI-Yun Hsieh
I-Yun Hsieh
XHXiaojia Huang
Xiaojia Huang
JLJie Li
Jie Li
WZWei Zhao
Wei Zhao
Glioblastoma multiforme (GBM), grade IV astrocytoma, is the most fatal malignant primary brain tumor. GBM contains functional subsets of cells called glioblastoma stem-like cells (GSCs), which are radioresistant and chemoresistant and eventually lead to tumor recurrence. Recent studies showed that GSCs reside in particular tumor niches that are necessary to support their behavior. To successfully eradicate GBM growth and recurrence, new strategies selectively targeting GSCs and/or their microenvironmental niche should be designed. In this regard, here we focus on elucidating the molecular mechanisms that govern these GSC properties and on understanding the mechanism of the microenvironmental signals within the tumor mass. Moreover, to overcome the blood–brain barrier, which represents a critical limitation of GBM treatments, a new drug delivery system should be developed. Nanoparticles can be easily modified by different methods to facilitate delivery efficiency of chemotherapeutics, to enhance the accumulation within the tumors, and to promote the capacity for targeting the GSCs. Therefore, nanotechnology has become the most promising approach to GSC-targeting therapy. Additionally, we discussed the future of nanotechnology-based targeted therapy and point out the disadvantages that should be overcome.

29 January 2022 in Oncogene
Verified
Journal Article
Open access
PDF file
QXQiong-Cong Xu
Qiong-Cong Xu
YTYi-Chih Tien
Yi-Chih Tien
YSYin-Hao Shi
Yin-Hao Shi
SCSiyun Chen
Siyun Chen
YZYing-Qin Zhu
Ying-Qin Zhu
XYXiao-yu Yin
Xiao-yu Yin
N6-methyladenosine (m6A) RNA methylation has recently been found involving in regulatory mechanism of the tumor progression. Our aim was to explore the biological function and clinical significance of the m6A methyltransferase METTL3 in intrahepatic cholangiocarcinoma (ICC). In this study, we revealed that METTL3 was upregulated and predicted poor prognosis of patients with ICC. Multivariate regression analysis demonstrated that METTL3 expression was an independent predictor for overall survival in patients with ICC. Moreover, METTL3 knockdown inhibited ICC progression, while METTL3 overexpression showed the opposite effect. METTL3 inhibitor STM2457 also showed anti-tumor effect in ICC. Mechanistically, METTL3 transcription was driven by H3K4me3 activation. Upregulation of METTL3 mediated m6A modification of IFIT2 mRNA and accelerated IFIT2 mRNA decay in a YTHDF2-dependent manner, which promoted the development of ICC and lead to poorer prognosis. In summary, our findings revealed that H3K4me3 activation-driven METTL3 transcription promotes ICC progression by YTHDF2-mediated IFIT2 mRNA degradation, suggesting that METTL3 may serve as a potential target for human ICC therapy.

25 August 2021 in Advanced Science
Verified
Journal Article
Open access
PDF file
BLBing Lu
Bing Lu
CZChangye Zou
Changye Zou
MYMeiling Yang
Meiling Yang
YHYangyang He
Yangyang He
JHJincan He
Jincan He
WZWei Zhao
Wei Zhao
Liquid–liquid phase‐separated (LLPS) transcriptional factor assemblies at super‐enhancers (SEs) provide a conceptual framework for underlying transcriptional control in mammal cells. However, the mechanistic understanding of LLPS in aberrant transcription driven by dysregulation of SEs in human malignancies is still elusive. By integrating SE profiling and core regulatory circuitry (CRC) calling algorithm, the CRC of metastatic and chemo‐resistant osteosarcoma is delineated. CRC components, HOXB8 and FOSL1, produce dense and dynamic phase‐separated droplets in vitro and liquid‐like puncta in cell nuclei. Disruption of CRC phase separation decreases the chromatin accessibility in SE regions and inhibits the release of RNA polymerase II from the promoter of SE‐driven genes. Importantly, absence of CRC key component causes a reduction in osteosarcoma tumor growth and metastasis. Moreover, it is shown that CRC condensates can be specifically attenuated by the H3K27 demethylase inhibitor, GSK‐J4. Pharmacological inhibition of the CRC phase separation results in metastasis suppression and re‐sensitivity to chemotherapy drugs in patient‐derived xenograft model. Taken together, this study reveals a previously unknown mechanism that CRC factors formed LLPS condensates, and provides a phase separation‐based pharmacological strategy to target undruggable CRC components for the treatment of metastatic and chemo‐resistant osteosarcoma.